OK Biotech Co., Ltd.

TWSE:4155 Stock Report

Market Cap: NT$2.9b

OK Biotech Balance Sheet Health

Financial Health criteria checks 5/6

OK Biotech has a total shareholder equity of NT$2.5B and total debt of NT$553.4M, which brings its debt-to-equity ratio to 22.5%. Its total assets and total liabilities are NT$3.4B and NT$973.4M respectively. OK Biotech's EBIT is NT$9.2M making its interest coverage ratio -9.7. It has cash and short-term investments of NT$192.8M.

Key information

22.5%

Debt to equity ratio

NT$553.41m

Debt

Interest coverage ratio-9.7x
CashNT$192.84m
EquityNT$2.46b
Total liabilitiesNT$973.44m
Total assetsNT$3.43b

Recent financial health updates

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Mar 17
OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08
Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Recent updates

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Aug 20
OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Apr 26
OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)

Apr 04
Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Mar 17
OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?

Mar 01
Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

Feb 15
Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

A Look At OK Biotech's (TPE:4155) Share Price Returns

Jan 31
A Look At OK Biotech's (TPE:4155) Share Price Returns

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

Jan 17
We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

Jan 03
Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

Dec 21
Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08
Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Nov 23
Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Financial Position Analysis

Short Term Liabilities: 4155's short term assets (NT$1.3B) exceed its short term liabilities (NT$707.7M).

Long Term Liabilities: 4155's short term assets (NT$1.3B) exceed its long term liabilities (NT$265.7M).

Debt to Equity History and Analysis

Debt Level: 4155's net debt to equity ratio (14.7%) is considered satisfactory.

Reducing Debt: 4155's debt to equity ratio has reduced from 42.1% to 22.5% over the past 5 years.

Debt Coverage: 4155's debt is not well covered by operating cash flow (13.2%).

Interest Coverage: 4155 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 05:42
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OK Biotech Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Yijun ChenSinoPac Securities Investment Service